Abstract: We conducted a 3-year follow-up study of 2,008 individuals for the persistence of antibody levels after vaccination with a recombinant hepatitis B vaccine. At 1 month after vaccination had been completed 96.3 % of subjects had acquired protective HB surface (HBs) antibody titers on passive hemagglutination assay (PHA) of 23, and 3 years after completion of the vaccination 63.1 % had acquired similar titers. The titer decreased below this level after 3 years in 34.5 % of subjects who had initially acquired protective antibody titers. The mean acquired HBs antibody titer on PHA was 25.8 at 1 month and 23.1 at 3 years after completion of the vaccination. The regression line for these changes was expressed as logY = 1.800 -0.24X by the least squares method. The antibody level was estimated to decrease to 23 at 37 months and to seronegativity at 75 months. On the basis of the relationship between PHA antibody titers and the period of their persistence, the persistence of antibody levels after vaccination with a recombinant vaccine can be estimated from the acquired antibody titer determined 1 month after completion of the vaccination, as with plasma-derived vaccines. (J. Oral Sci. 42, 147-150, 2000) 
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Abstract: We conducted a 3-year follow-up study of 2,008 individuals for the persistence of antibody levels after vaccination with a recombinant hepatitis B vaccine. At 1 month after vaccination had been completed 96.3 % of subjects had acquired protective HB surface (HBs) antibody titers on passive hemagglutination assay (PHA) of 23, and 3 years after completion of the vaccination 63.1 % had acquired similar titers. The titer decreased below this level after 3 years in 34.5 % of subjects who had initially acquired protective antibody titers. The mean acquired HBs antibody titer on PHA was 25.8 at 1 month and 23.1 at 3 years after completion of the vaccination. The regression line for these changes was expressed as logY = 1.800 -0.24X by the least squares method. The antibody level was estimated to decrease to 23 at 37 months and to seronegativity at 75 months. On the basis of the relationship between PHA antibody titers and the period of their persistence, the persistence of antibody levels after vaccination with a recombinant vaccineIntroduction It is not rare for dental care providers to come into contact with patients' blood in clinical practice. Therefore, protection against infectious diseases that can be mediated by blood, such as hepatitis B virus (HBV) infection, is a critical issue in dental practice. A useful strategy for prevention of these infections is to increase the resistance of the host, particularly by vaccination. Prevention of HBV infection by hepatitis B (HB) vaccination has been practiced for nearly 15 years. The vaccines in use were plasma-derived vaccines in the initial stage, but yeastderived recombinant HB vaccines are currently predominant. Data on the rate of acquisition of antibodies and their diminution after vaccination with a recombinant HB vaccine based on detailed surveys and studies are lacking at present, in contrast with data on plasma-derived vaccines (1). In particular, little has been reported on decreases in acquired antibodies after vaccination (2, 3) , and the pattern of decrease in acquired resistance after vaccination with a plasma-derived vaccine has been used as a surrogate. The key issue in vaccination in a high-risk group is the maintenance of acquired antibodies at levels high enough to prevent infection. However, currently there is no routine follow-up monitoring of antibody levels, and the pattern of decreases in acquired antibodies after vaccination with a recombinant HBV vaccine remains unclear.
Therefore, individuals may lose resistance to HBV after vaccination, even though they think that they are protected. In this connection, the present study was designed to determinine the optimal interval for vaccination with a in the subjects who had initial postvaccination antibody titers of 27 or more, 26, 25, and 24, respectively. In the group as a whole, the antibody titer was estimated to decrease to 23 at 37 months and to seronegativity at 75 months. Discussion Prevention of type B hepatitis by means of HB vaccination has been practiced for more than 10 years, and its great contribution to protection of infants from becoming carriers through mother-to-child transmission has been recognized (6).
However, there have been few reports on prevention of nosocomial infection by horizontal transmission. The available study of this kind was Rosen. et al. (7), who examined long-termed study of infections among hospital employees. According to Hadler et al.(8) , the estimated protective level of HBS antibody against HB virus is 10 mIU/ml, which corresponds to an antibody titer of 23 by PHA. A survey of accidental HB virus infections pointed out that, in fact, the boundary between developing and resisting the infectious disease was a PHA titer of 23 in the host. Taking this finding into account, the percentage of subjects who acquired protective levels of antibodies with the recombinant HB vaccine should be regarded as 96.3 % at 1 month and 63.1 % at 3 years, rather than 98.1 % at 1 month and 80.3 % at 3 years.
Nevertheless, these percentages are about 20 % higher than the corresponding figures reported for plasmaderived vaccines. Changes in antibody levels in the subjects of our study high-, intermediateand lowresponse groups classified in ten-ns of the antibody titer obtained 1 month after completion of the vaccination (Fig. 2) .
Although our results were expressed as straight lines because there were only two measuring points, it is apparent that the decreasing is similar for the result from plasma-devised vaccine, reported by Robert. et al. (9) and our study of vaccine. It is possible to estimate the persistence of antibody levels on the basis of the antibody titer determined 1 (3), they observed that HBs antibody decreased to a level of 10 mIU/ml at 37 months and to seronegativity at 77 months. Therefore, it is reasonable to conclude that the pattern of decreases in the antibody titer after vaccination with a recombinant vaccine is similar to that with a plasma-derived vaccine. The results of the present study showed that the HBs antibody titer would decrease to 1/23 in 3 years, with an annual decrease of about 1/2. Figure 3 is a schematic diagram of such a decrease in relation to the initially acquired antibody level. If booster immunization is given by the time the PHA titer reaches 23 in this schema, the protective antibody level can be maintained. For this purpose, the minimum requirement for effective prevention of HB infection is that each person vaccinated be aware of his or her own acquired level of antibodies by undergoing measurement of the antibody level after vaccination. 
